Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-9256 plus Tegobuvir in chronic genotype 1 hepatitis C
NCT01072695Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2010
- Primary completion
- Oct 2010
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of GS-9256 and tegobuvir in hepatitis C (HCV) (3 arms), sponsored by Gilead Sciences. Primary endpoints: Rapid Virologic Response at Day 28 and Adverse Events and Safety Parameters at 6 weeks. Started Feb 2010; status: completed.
02
Drugs
GS-9256tegobuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01072695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01072695.